Benjamin Emmanuel1, Samer S El-Kamary2, Laurence S Magder2, Kristen A Stafford1,2, Man E Charurat3, Cheryl Chairez4, Mary McLaughlin4, Colleen Hadigan4, Ludmila Prokunina-Olsson5, Thomas R O'Brien5, Henry Masur6, Shyam Kottilil1. 1. Division of Clinical Care and Research, Institute of Human Virology, Baltimore, Maryland. 2. Department of Epidemiology and Public Health, Baltimore, Maryland. 3. Department of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland. 4. National Institute of Allergy and Infectious Diseases, Bethesda, Maryland. 5. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. 6. Clinical Center, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: Clearance of hepatitis C virus (HCV) results in rapid changes in metabolic parameters early in direct-acting antiviral (DAA) therapy. Long-term changes after sustained virologic response (SVR) remain unknown. METHODS: We investigated longitudinal changes in metabolic and inflammatory outcomes in chronic hepatitis C (CHC) patients: low-density lipoprotein (LDL), high-density lipoprotein, triglycerides, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) using a general linear model for repeated measurements at 5 clinical time points and by human immunodeficiency virus (HIV) coinfection and IFNL4 genotype. RESULTS: The mean LDL increased markedly during DAA therapy (pre-DAA, 86.6 to DAA, 107.4 mg/dL; P < .0001), but then it decreased to 97.7 mg/dL by post-SVR year 1 (P < .001 compared with DAA; P = .0013 compared with SVR). In patients who carry the IFNL4-ΔG allele, mean LDL increased during treatment, then decreased at post-SVR year 1; however, in patients with TT/TT, genotype did not change during and after DAA treatment. The mean ALT and AST normalized rapidly between pre-DAA and DAA, whereas only mean ALT continued to decrease until post-SVR. Metabolic and inflammatory outcomes were similar by HIV-coinfection status. CONCLUSIONS: Changes in LDL among CHC patients who achieved SVR differed by IFNL4 genotype, which implicates the interferon-λ4 protein in metabolic changes observed in HCV-infected patients.
BACKGROUND: Clearance of hepatitis C virus (HCV) results in rapid changes in metabolic parameters early in direct-acting antiviral (DAA) therapy. Long-term changes after sustained virologic response (SVR) remain unknown. METHODS: We investigated longitudinal changes in metabolic and inflammatory outcomes in chronic hepatitis C (CHC) patients: low-density lipoprotein (LDL), high-density lipoprotein, triglycerides, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) using a general linear model for repeated measurements at 5 clinical time points and by human immunodeficiency virus (HIV) coinfection and IFNL4 genotype. RESULTS: The mean LDL increased markedly during DAA therapy (pre-DAA, 86.6 to DAA, 107.4 mg/dL; P < .0001), but then it decreased to 97.7 mg/dL by post-SVR year 1 (P < .001 compared with DAA; P = .0013 compared with SVR). In patients who carry the IFNL4-ΔG allele, mean LDL increased during treatment, then decreased at post-SVR year 1; however, in patients with TT/TT, genotype did not change during and after DAA treatment. The mean ALT and AST normalized rapidly between pre-DAA and DAA, whereas only mean ALT continued to decrease until post-SVR. Metabolic and inflammatory outcomes were similar by HIV-coinfection status. CONCLUSIONS: Changes in LDL among CHCpatients who achieved SVR differed by IFNL4 genotype, which implicates the interferon-λ4 protein in metabolic changes observed in HCV-infectedpatients.
Authors: Anu Osinusi; Anita Kohli; Miriam M Marti; Amy Nelson; Xiaozhen Zhang; Eric G Meissner; Rachel Silk; Kerry Townsend; Phillip S Pang; G Mani Subramanian; John G McHutchison; Anthony S Fauci; Henry Masur; Shyam Kottilil Journal: Ann Intern Med Date: 2014-11-04 Impact factor: 25.391
Authors: P J Clark; A J Thompson; M Zhu; D M Vock; Q Zhu; D Ge; K Patel; S A Harrison; T J Urban; S Naggie; J Fellay; H L Tillmann; K Shianna; S Noviello; L D Pedicone; R Esteban; P Kwo; M S Sulkowski; N Afdhal; J K Albrecht; D B Goldstein; J G McHutchison; A J Muir Journal: J Viral Hepat Date: 2012-02-22 Impact factor: 3.728
Authors: Anita Kohli; Sarah Kattakuzhy; Sreetha Sidharthan; Amy Nelson; Mary McLaughlin; Cassie Seamon; Eleanor Wilson; Eric G Meissner; Zayani Sims; Rachel Silk; Chloe Gross; Elizabeth Akoth; Lydia Tang; Angie Price; Tim A Jolley; Benjamin Emmanuel; Michael Proschan; Gebeyehu Teferi; Jose Chavez; Stephen Abbott; Anuoluwapo Osinusi; Hongmei Mo; Michael A Polis; Henry Masur; Shyam Kottilil Journal: Ann Intern Med Date: 2015-11-24 Impact factor: 25.391
Authors: Kerry Townsend; Eric G Meissner; Sreetha Sidharthan; Maureen Sampson; Alan T Remaley; Lydia Tang; Anita Kohli; Anu Osinusi; Henry Masur; Shyam Kottilil Journal: AIDS Res Hum Retroviruses Date: 2015-12-15 Impact factor: 2.205
Authors: Christoph Welsch; Mira Efinger; Michael von Wagner; Eva Herrmann; Stefan Zeuzem; Tania M Welzel; Christian M Lange Journal: PLoS One Date: 2017-02-14 Impact factor: 3.240